Emerging biomolecules for practical theranostics of liver hepatocellular carcinoma

Most cases of hepatocellular carcinoma (HCC) are able to be diagnosed through regular surveillance in an identifiable patient population with chronic hepatitis B or cirrhosis. Nevertheless, 50% of global cases might present incidentally owing to symptomatic advanced-stage HCC after worsening of live...

Full description

Saved in:
Bibliographic Details
Published in:Annals of hepatology 2023-11, Vol.28 (6), p.101137, Article 101137
Main Authors: Hu, Miner, Xia, Xiaojun, Chen, Lichao, Jin, Yunpeng, Hu, Zhenhua, Xia, Shudong, Yao, Xudong
Format: Article
Language:English
Subjects:
Biomarkers, Tumor - genetics
Carcinoma, Hepatocellular - diagnosis
Carcinoma, Hepatocellular - therapy
Deep learning
DNA Methylation
Hepatocellular carcinoma diagnosis
Humans
Liquid Biopsy
Liver Neoplasms - diagnosis
Liver Neoplasms - therapy
Precision Medicine
Systemic therapies
Theranostic Nanomedicine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Most cases of hepatocellular carcinoma (HCC) are able to be diagnosed through regular surveillance in an identifiable patient population with chronic hepatitis B or cirrhosis. Nevertheless, 50% of global cases might present incidentally owing to symptomatic advanced-stage HCC after worsening of liver dysfunction. A systematic search based on PUBMED was performed to identify relevant outcomes, covering newer surveillance modalities including secretory proteins, DNA methylation, miRNAs, and genome sequencing analysis which proposed molecular expression signatures as ideal tools in the early-stage HCC detection. In the face of low accuracy without harmonization on the analytical approaches and data interpretation for liquid biopsy, a more accurate incidence of HCC will be unveiled by using deep machine learning system and multiplex immunohistochemistry analysis. A combination of molecular-secretory biomarkers, high-definition imaging and bedside clinical indexes in a surveillance setting offers a comprehensive range of HCC potential indicators. In addition, the sequential use of numerous lines of systemic anti-HCC therapies will simultaneously benefit more patients in survival. This review provides an overview on the most recent developments in HCC theranostic platform.
ISSN:1665-2681
2659-5982
DOI:10.1016/j.aohep.2023.101137